NCT07589478

Brief Summary

The goal of this observational study is to evaluate the clinical and radiographic outcomes of the biological enhancement of the arthroscopic rotator cuff repair with stem cells from the acromial bursa and PRP in individuals who undergo arthroscopic cuff repair The main question it aims to answer is: Do the stems cells from the acromial bursa and PRP promote healing and produce better results in arthroscopic cuff repair? Researchers will compare this population to three others the first do bnot receive any biological enchancement, the second receive only stem cells and the third receive only PRP to see if there are any differences.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
20mo left

Started May 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
May 2026Feb 2028

First Submitted

Initial submission to the registry

March 23, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 15, 2026

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2028

Last Updated

May 19, 2026

Status Verified

May 1, 2026

Enrollment Period

8 months

First QC Date

March 23, 2026

Last Update Submit

May 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Functional Outcome Assessed by Constant-Murley Score and ASES Score

    The primary outcome measure will be the functional outcome of the shoulder assessed using the Constant-Murley Score and the American Shoulder and Elbow Surgeons (ASES) score at 3, 6, and 12 months postoperatively. Both scores are validated instruments evaluating pain, daily activities, and shoulder function, with higher scores indicating better clinical outcomes.

    The primary outcome measure will be the functional outcome of the shoulder assessed using the Constant-Murley Score and the American Shoulder and Elbow Surgeons (ASES) score at 3, 6, and 12 months postoperatively. Both scores are validated instruments ev

Secondary Outcomes (5)

  • Rotator Cuff Tendon Integrity Assessed by MRI (Sugaya Classification)

    12 months postoperatively

  • Pain Intensity Assessed by Numeric Rating Scale (NRS)

    3, 6, and 12 months postoperatively

  • Health-Related Quality of Life Assessed by SF-12

    3, 6, and 12 months postoperatively

  • Patient Satisfaction

    3, 6, and 12 months postoperatively

  • Postoperative Complications and Retear Rate

    Up to 12 months postoperatively

Study Arms (4)

GROUP A

EXPERIMENTAL

(MSCs + PRP): 1 ml of a mixture of subacromial bursa and 3 ml of PRP will be placed in the bone-tendon junction after completion of the arthroscopic suturing

Biological: Subacromial Bursa Tissue ReimplantationProcedure: Arthroscopic Rotator Cuff RepairBiological: Platelet-Rich Plasma (PRP) Injections

GROUP B

EXPERIMENTAL

1 ml of a mixture of subacromial bursal tissue fragments without PRP will be placed at the bone-tendon junction immediately after completion of the arthroscopic repair.

Biological: Subacromial Bursa Tissue ReimplantationProcedure: Arthroscopic Rotator Cuff Repair

GROUP C

EXPERIMENTAL

3 ml of PRP will be placed at the bone-tendon junction immediately after completion of the arthroscopic repair.

Procedure: Arthroscopic Rotator Cuff RepairBiological: Platelet-Rich Plasma (PRP) Injections

GROUP D

PLACEBO COMPARATOR

3 ml of saline will be placed at the bone-tendon junction immediately after completion of the arthroscopic repair.

Procedure: Arthroscopic Rotator Cuff RepairOther: Normal Saline (0.9% NaCl)

Interventions

Autologous minced subacromial bursal tissue harvested arthroscopically using a tissue collection device and applied at the bone-tendon interface immediately after rotator cuff repair.

GROUP AGROUP B

Standard arthroscopic repair of full-thickness isolated supraspinatus tendon tears using suture anchors.

GROUP AGROUP BGROUP CGROUP D

Autologous platelet-rich plasma prepared from preoperatively collected peripheral blood and applied at the bone-tendon interface immediately after repair completion.

GROUP AGROUP C

Three milliliters of sterile normal saline applied at the bone-tendon interface immediately after arthroscopic rotator cuff repair as placebo comparator.

GROUP D

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients considered eligible for arthroscopic rotator cuff repair using suture anchors.
  • Ability and willingness to provide written informed consent. Willingness and ability to comply with the study protocol and scheduled follow-up visits.

You may not qualify if:

  • Previous surgery on the affected shoulder. Glenohumeral osteoarthritis or advanced cuff tear arthropathy. Active infection or systemic inflammatory disease affecting the shoulder. Use of other biological augmentation techniques during surgery, such as collagen patch, stem cells, bone marrow aspirate concentrate, or other scaffold-based augmentation.
  • Inability to provide informed consent. Inability or unwillingness to comply with the postoperative rehabilitation protocol or follow-up schedule.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Rotator Cuff Injuries

Interventions

InjectionsSaline Solution

Condition Hierarchy (Ancestors)

RuptureWounds and InjuriesShoulder InjuriesTendon Injuries

Intervention Hierarchy (Ancestors)

Drug Administration RoutesDrug TherapyTherapeuticsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Andriani Zafeiri

    PRINCIPAL INVESTIGATOR

Central Study Contacts

ANDRIANI ZAFEIRI, MEDICAL DOCTOR

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MEDICAL DOCTOR

Study Record Dates

First Submitted

March 23, 2026

First Posted

May 15, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

February 1, 2028

Last Updated

May 19, 2026

Record last verified: 2026-05